Anzeige
Mehr »
Sonntag, 27.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JS1K | ISIN: IE00B4Q5ZN47 | Ticker-Symbol: J7Z
Tradegate
25.07.25 | 19:15
100,40 Euro
-0,30 % -0,30
1-Jahres-Chart
JAZZ PHARMACEUTICALS PLC Chart 1 Jahr
5-Tage-Chart
JAZZ PHARMACEUTICALS PLC 5-Tage-Chart
RealtimeGeldBriefZeit
99,88101,5026.07.
100,50100,9525.07.

Aktuelle News zur JAZZ PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrJazz Pharmaceuticals plc - 8-K, Current Report1
DiJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025253DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after...
► Artikel lesen
DiWhere Jazz Pharmaceuticals Stands With Analysts3
15.07.Deutsche Bank stuft Jazz Pharmaceuticals mit "Buy" ein und sieht attraktiven Einstiegszeitpunkt8
JAZZ PHARMACEUTICALS Aktie jetzt für 0€ handeln
15.07.Deutsche Bank initiates Jazz Pharmaceuticals stock with Buy rating1
14.07.Jazz Pharmaceuticals (JAZZ) Highlights Growth at Goldman Sachs Healthcare Conference5
10.07.Jazz Pharmaceuticals Names Renee Gala as President & CEO1
10.07.Jazz Pharmaceuticals names Renee Gala as CEO1
10.07.Jazz Pharmaceuticals names Renee Gala as next CEO2
10.07.Jazz Pharmaceuticals plc - 8-K, Current Report-
10.07.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer954- Selection Follows Robust Succession Process Led by the Board - - Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors - DUBLIN, July 10, 2025 /PRNewswire/...
► Artikel lesen
08.07.EC approves Jazz Pharmaceuticals' Ziihera for advanced biliary tract cancer3
02.07.EC approves Jazz Pharmaceuticals' Ziihera for biliary tract cancer3
01.07.Jazz Pharmaceuticals gets EU nod for Ziihera4
01.07.Jazz Pharma Says EU Grants Conditional MA To Ziihera For Advanced HER2-Positive Biliary Tract Cancer1
12.06.Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav®15
10.06.Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca8
10.06.Jazz Pharma Says FDA Granted Priority Review For Zepzelca And Tecentriq Combo For ES-SCLC3
10.06.Jazz Pharmaceuticals plc: Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer171Target Action (PDUFA) Date set for October 7, 2025 Application based on data from IMforte, the first Phase 3 trial demonstrating statistically significant and clinically...
► Artikel lesen
10.06.Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025107First presentation of the Phase 4 XYLO switch study reports blood pressure reductions in patients with narcolepsy when switching from twice-nightly high- to low-sodium...
► Artikel lesen
Weiter >>
93 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1